In recent years, because the dry skin problem has become very common, it is getting the more important to preserve the barrier function of the skin. Although protecting the skin against water loss is one of the representative factors of its barrier capabilities, there is no report until now about the relationship between daily use of bath liquid and the moisture-keeping capacity of the skin.   In this study we examined how the skin condition can be improved after 14 straight days of employment of our bath liquid ‘Ulmore®’including Polyquaternium-10 and several moisturizing ingredients. Polyquaternium-10 is a Cationized Cellulose and is widely formulated in shampoos and hair conditioners.   We found that the application of Ulmore® for 10 or 14 days significantly maintained sratum corneum water content (SCWC) and transepidermal water loss (TEWL) compared with the placebo application. This result suggests that this is because our bath liquid covered the stratum corneum and protected the skin from water loss caused by the environmental factors like low humidity.   Thus we conclude that daily use of the bath liquid has a beneficial effect on skin moisture.

OBJECTIVES: The favorable safety and consistent effectiveness of monthly intravenous (IV) ibandronate injections was demonstrated in a prospective, postmarketing, observational study in Japanese patients with osteoporosis. Here, we present subgroup analyses from the study. METHODS: Lumbar spine (L2–4) bone mineral density (BMD) gains were assessed in the following subgroups: aged <75 or ≥75 years, absence or presence of vertebral fractures, previous bisphosphonate (BP) treatment, and concomitant versus naïve osteoporosis drug treatment. The cumulative incidence of fractures and relative change in bone turnover markers were also examined. RESULTS: Of 1062 enrolled patients, 1025 received monthly IV ibandronate 1 mg and were assessed for 12 months. BMD gains with ibandronate were comparable, irrespective of older age or prevalent fractures. Overall, 515 patients (50.2%) had previously received osteoporosis treatment; of these, 166 (16.1%) received other BPs. Mean BMD changes were 3.69% (95% confidence interval [CI], 0.89%–6.50%) in patients previously treated with other BPs, and 4.26% (95% CI, 2.88%–5.64%) in patients who had not received prior osteoporosis treatment. Among the 510 patients (49.7%) concomitantly prescribed active vitamin D drugs, mean BMD changes were 5.74% (95% CI, 2.53%–8.95%) with eldecalcitol versus 3.54% (95% CI, 1.98%–5.10%) with ibandronate alone. The lowest fracture incidence was observed with the combination of ibandronate and eldecalcitol, but differences between the subgroups were not statistically significant. CONCLUSIONS: Monthly IV ibandronate demonstrated comparable BMD gains in the patient subgroups analyzed. Concomitant use of ibandronate with eldecalcitol showed a trend of higher BMD gains and lower fracture incidence than ibandronate alone.
Asian Continental Ancestry Group ; Bone Density ; Bone Remodeling ; Humans ; Incidence ; Japan ; Observational Study ; Osteoporosis ; Prospective Studies ; Spine ; Vitamin D